Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

New Application Note Addresses Benefits of aCGH/SNP Arrays

Published: Friday, March 22, 2013
Last Updated: Friday, March 22, 2013
Bookmark and Share
Detecting CNVs and ROH on a single array - streamlining the workflow.

Oxford Gene Technology (OGT) has produced a new, free-to-download application note on combined array comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) arrays.

The application note, titled ‘Detecting copy number variants and runs of homozygosity on a single array - challenges and applications’ aims to support researchers in navigating this combined approach for the simultaneous detection of copy number variations (CNVs) and runs of homozygosity (ROH).

aCGH has established itself as the “gold-standard” platform for array-based CNV detection.

Recent advances have enabled the combination of aCGH probes for CNV detection with probes able to detect SNPs.

Ideal for clinical genetics researchers, the application note highlights the importance and benefits of these combined probe arrays in the detection of various genetic conditions.

For example, OGT’s CytoSure aCGH +SNP arrays allow any reference DNA to be used and no restriction digest of the sample is required.

This means that labelling and hybridization steps can be competed in a single day - which is significantly quicker than typical SNP platforms - while providing information on changes in copy number and regions of homozygosity, and integrating into existing workflows.

The OGT arrays have been research-validated to provide informative, biologically relevant SNP data for various genetic aberrations such as uniparental disomy (UDP), mosaic aneuploidy and ROH, without compromising on high-quality CNV data.

CytoSure aCGH +SNP arrays are available for constitutional, cancer and molecular genetics research.

Each array purchase also comes with complimentary access to OGT’s powerful, user-friendly CytoSure Interpret Software, a CNV and SNP data analysis package which contains innovative features to minimize user intervention and maximize consistency and speed of data interpretation.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT’s miRNA Profiling Service Provides Answers for Disease Research
Company has designed the microRNA profiling service designed to help researchers accelerate their discoveries.
Friday, May 16, 2008
Scientific News
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!